Resources

YCANTH™ resources

For additional hands-on support, please call 1-877-VERRICA (1-877-837-7422)

Training information

Verrica offers in-office training to give your practice the best experience with the YCANTH applicator.

Request an in-office training:

REGISTER NOW

Applicator is not to scale.

Watch the YCANTH treatment experience below

Before administering YCANTH, please review the complete Instructions for Use and full Prescribing Information.

YCANTH Copay Assistance Program*

Copay savings for commercially insured patients*

With the YCANTH Copay Assistance Program, most of your commercially insured patients may pay as little as $25 per applicator. Eligibility requirements apply.

For qualified patients, copay amounts are based on several factors:

  • Whether your patient's insurance covers YCANTH
  • The type of commercial insurance your patient has
  • Whether or not your patient has met their deductible

Most patients pay as little as:

$25

If deductible has not been met, or insurance does not cover YCANTH, patient pays practice no more than $125 per applicator.

Remind patients that flexible spending accounts (FSA) or health savings accounts (HSA) can help cover copay expenses. Healthcare expense accounts can help offset qualified out-of-pocket expenses. Encourage patients to check with their program provider. Additional terms and conditions may apply.

*

Copay Assistance Program is solely for patients' charges incurred in the use of YCANTH (cantharidin) topical solution and does not include any other related charges. For all qualified patients, Verrica is responsible for all YCANTH product costs under the Program amount and excluding the copay requirement. Your insurance provider can provide the most accurate explanation of all charges. Approval to the Program is not guaranteed. Program has an annual maximum benefit of $2,405 or 4 treatments for YCANTH, whichever occurs first. Until the patient reaches the maximum Program benefit, providing healthcare professionals may not charge the patient more than the applicable Program allowance. Patient will bear financial responsibility for all costs not covered by commercial insurance exceeding maximum benefit for YCANTH. THIS IS NOT INSURANCE. Not valid for prescriptions paid, in whole or in part, by Medicaid, Medicare, VA, DOD, TRICARE®, or other federal or state programs including any state pharmaceutical assistance programs. This Program is not valid where prohibited by law, taxed or restricted. Verrica reserves the right to rescind, revoke, terminate, or amend this offer, eligibility, and terms of use at any time without notice. Additional terms and conditions may apply.

TRICARE® is a registered trademark of the Department of Defense (DOD), DHA.

Enrolling patients in the YCANTH Copay Assistance Program

There are 2 ways to enroll patients in the Copay Assistance program, based on whether YCANTH is obtained through Buy & Bill or our Specialty Pharmacy (Nufactor®).
Click here for more information.

Buy & Bill Enrollment

  • Enroll your patient electronically via Y-Access™ Support Solutions; visit Y-AccessSupport.com
  • Complete the Enrollment Form; have the patient/caregiver fill out a Patient Authorization Form
  • Y-Access Support Solutions will enroll qualifying patients into the Verrica Copay Assistance Program
  • To view the status of copay claims, visit Y-AccessCopay.com or call 1-844-533-1069

Specialty Pharmacy Enrollment

  • Submit a YCANTH prescription to Nufactor, Verrica's dedicated Specialty Pharmacy
  • Nufactor will contact the patient directly to verify coverage and complete the enrollment process

Photo is illustrative and not representative of all patients.

Resources designed to help your practice with acquisition and reimbursement

Buy & Bill
Office Resource

Use this resource to access YCANTH inventory with no up-front costs through FFF Enterprises

Specialty Pharmacy
Office Resource

Use this resource when prescribing YCANTH through our dedicated Specialty Pharmacy, Nufactor

Billing and
Coding Guide

Reference this guide for proper billing and coding practices

Y–Access Support Solutions
Training Portal

Learn about the integrated benefits of this comprehensive online solution to streamline drug eligibility, approval, and reimbursement of Buy & Bill services

FFF Enterprises Specialty
Distribution

Discover how to access YCANTH with no upfront costs and a flexible inventory management solution to manage your practice needs

Specialty Pharmacy
Program

See how your practice can submit prescriptions for coordinated Specialty Pharmacy fulfillment

For more information about the YCANTH Copay Assistance Program, visit Y-AccessSupport.com or download the information sheet below

Explore YCANTH support and additional resources for your patients

Copay Assistance Program

Learn more about the YCANTH Copay Assistance Program for eligible patients

Patient brochure

Give your patients key information about molluscum and their treatment with YCANTH. For additional support, offer your patients and caregivers important instructions to follow when treated with YCANTH

Support for your practice

Sourcing and reimbursement assistance is available.

LEARN MORE

For medical questions and information, please call 1-877-VERRICA (1-877-837-7422)

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: None.

WARNINGS AND PRECAUTIONS:

  • YCANTH is for topical use only. YCANTH is not for oral, mucosal, or ophthalmic use. Life threatening or fatal toxicities can occur if YCANTH is administered orally. Avoid contact with the treatment area, including oral contact, after treatment. Ocular toxicity can occur if YCANTH comes in contact with eyes. If YCANTH gets in eyes, flush eyes with water for at least 15 minutes.

INDICATION

YCANTH (cantharidin) topical solution, 0.7% is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: None.

WARNINGS AND PRECAUTIONS:

  • YCANTH is for topical use only. YCANTH is not for oral, mucosal, or ophthalmic use. Life threatening or fatal toxicities can occur if YCANTH is administered orally. Avoid contact with the treatment area, including oral contact, after treatment. Ocular toxicity can occur if YCANTH comes in contact with eyes. If YCANTH gets in eyes, flush eyes with water for at least 15 minutes.
  • Local Skin Reactions: Reactions at the application site may occur, including vesiculation, pruritus, pain, discoloration, and erythema. Avoid application near eyes and mucosal tissue, and to healthy skin. If YCANTH contacts any unintended surface, or healthy skin, immediately remove. If severe local skin reactions occur, remove prior to the recommended 24 hours after treatment.
  • YCANTH is flammable, even after drying. Avoid fire, flame or smoking near lesion(s) during treatment and after application until removed.

ADVERSE REACTIONS:

The most common (incidence ≥1%) reactions are the following local skin reactions at the application site: vesiculation, pain, pruritus, scabbing, erythema, discoloration, application site dryness, edema, and erosion. Local skin reactions at the application site were observed in 97% of subjects treated with YCANTH during clinical trials. These local skin reactions are expected and related to the anticipated blistering response of the skin to cantharidin.

DRUG INTERACTIONS:

No studies evaluating the drug interaction potential of cantharidin have been conducted.

USE IN SPECIFIC POPULATIONS:

Pregnancy: There are no available data with use of YCANTH in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Given that systemic exposure to cantharidin following topical administration is low, maternal use is not expected to result in fetal exposure to the drug.

Lactation: Avoid application of YCANTH topical solution to areas with increased risk for potential ingestion by or ocular exposure to the breastfeeding child.

OVERDOSAGE:

Oral ingestion of cantharidin has resulted in renal failure, blistering and severe damage to the gastrointestinal tract, coagulopathy, seizures, and flaccid paralysis.

Please see full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact Verrica Pharmaceuticals Inc. at 1-877-VERRICA (1-877-837-7422), or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Local skin reactions are expected and should be reported if they are severe.